Year archive

FIREBRICK PHARMA LIMITED — 2022 filings

All 63 regulatory filings released by FIREBRICK PHARMA LIMITED (FRE) in 2022, sourced directly from the official regulator.

63 Filings

2022 Period

2022 filings (63)

Filing	Released	Lang
Nasodine Appeal Timetable Agreed at AAT Conference 2 pages 128.2KB Regulatory Filings	2022-11-30	English
Constitution 65 pages 455.9KB Regulatory Filings	2022-11-23	English
Notification regarding unquoted securities - FRE 5 pages 26.4KB Regulatory Filings	2022-11-23	English
Notification regarding unquoted securities - FRE 5 pages 26.4KB Regulatory Filings	2022-11-23	English
Change of Director's Interest Notice - Richard Treagus 2 pages 277.9KB Regulatory Filings	2022-11-23	English
Change of Director's Interest Notice - Phyllis Gardner 3 pages 282.5KB Regulatory Filings	2022-11-23	English
Annual General Meeting Presentation 28 pages 1.2MB Regulatory Filings	2022-11-22	English
Results of Annual General Meeting 2 pages 139.5KB Regulatory Filings	2022-11-22	English
Nasodine Composition Patent Accepted in Australia 2 pages 147.9KB Regulatory Filings	2022-11-13	English
Firebrick CFO and Accounting Change 2 pages 119.2KB Regulatory Filings	2022-11-13	English
Firebrick Receives $1.08m R&D Tax Incentive 2 pages 132.4KB Regulatory Filings	2022-11-08	English
Proposed issue of securities - FRE 6 pages 30.5KB Regulatory Filings	2022-10-31	English
September 2022 Quarterly Activity Report & Appendix 4C 8 pages 228.4KB Regulatory Filings	2022-10-30	English
Firebrick Update on Nasodine Phase 3 Trial 3 pages 164.8KB Regulatory Filings	2022-10-30	English
Nasodine Patent Granted in Singapore 2 pages 155.8KB Regulatory Filings	2022-10-24	English
Letter to Shareholders & Notice of AGM & Proxy Form 36 pages 1.0MB Regulatory Filings	2022-10-20	English
Annual Report to Shareholders 49 pages 7.8MB Regulatory Filings	2022-10-20	English
Notification of cessation of securities - FRE 4 pages 24.3KB Regulatory Filings	2022-10-09	English
Notice of AGM and Closing Date for Director Nominations 2 pages 120.7KB Regulatory Filings	2022-09-27	English
Firebrick announces formation of Scientific Advisory Board 3 pages 142.1KB Regulatory Filings	2022-09-13	English
Appendix 4E & Annual Report 52 pages 7.9MB Regulatory Filings	2022-08-22	English
Appendix 4G 13 pages 275.8KB Regulatory Filings	2022-08-22	English
Corporate Governance Statement 14 pages 348.2KB Regulatory Filings	2022-08-22	English
Application for quotation of securities - FRE 6 pages 27.7KB Regulatory Filings	2022-08-02	English
Cleansing Notice 2 pages 124.2KB Regulatory Filings	2022-08-02	English
June 2022 Quarterly Activity Report & Appendix 4C 9 pages 233.2KB Regulatory Filings	2022-07-28	English
Firebrick Presents at Euroz Hartleys Healthcare Conference 17 pages 1.4MB Regulatory Filings	2022-07-25	English
Trading Halt 2 pages 631.4KB Regulatory Filings	2022-07-06	English
Outcome of s60 appeal for Nasodine and next steps 2 pages 129.8KB Regulatory Filings	2022-07-06	English
Notification of cessation of securities - FRE 4 pages 24.3KB Regulatory Filings	2022-06-21	English
Initial Director's Interest Notice - Richard Treagus 2 pages 241.0KB Regulatory Filings	2022-05-31	English
Firebrick Appoints Dr Richard Treagus as Director 2 pages 134.6KB Regulatory Filings	2022-05-24	English
Nasodine Patent Granted in Malaysia 2 pages 156.2KB Regulatory Filings	2022-05-24	English
Proposed issue of securities - FRE 6 pages 30.4KB Regulatory Filings	2022-05-24	English
Firebrick starts Phase 3 common cold trial of Nasodine 4 pages 149.0KB Regulatory Filings	2022-05-02	English
Firebrick starts COVID-19 trial of Nasodine 3 pages 158.5KB Regulatory Filings	2022-04-25	English
March 2022 Quarterly Activity Report & Appendix 4C 9 pages 256.3KB Regulatory Filings	2022-04-25	English
Investor Presentation - Euroz Hartleys Rottnest Conference 13 pages 1.6MB Regulatory Filings	2022-03-10	English
Investor Presentation - Euroz Hartleys Rottnest Conference 13 pages 1.7MB Regulatory Filings	2022-03-10	English
FRE to file appeal seeking immediate approval of Nasodine 2 pages 127.6KB Regulatory Filings	2022-02-28	English
Nasodine US Patent Granted for COVID-19 2 pages 142.1KB Regulatory Filings	2022-02-16	English
31 December Interim Financial Report & Appendix 4D 23 pages 496.3KB Regulatory Filings	2022-02-10	English
Nasodine in vitro and pilot human COVID-19 studies published 2 pages 150.3KB Regulatory Filings	2022-02-09	English
Nasodine COVID-19 trial receives SAHPRA approval 2 pages 147.9KB Regulatory Filings	2022-01-31	English
ASX Market Release - Admission and Quotation 2 pages 457.0KB Regulatory Filings	2022-01-24	English
Appendix 1A 1 page 130.6KB Regulatory Filings	2022-01-24	English
Information Form and Checklist 16 pages 338.7KB Regulatory Filings	2022-01-24	English
Prospectus 131 pages 4.7MB Regulatory Filings	2022-01-24	English
Constitution 64 pages 462.2KB Regulatory Filings	2022-01-24	English
Annual Report 30 June 2020 29 pages 1.9MB Regulatory Filings	2022-01-24	English
Annual Report 30 June 2021 35 pages 963.9KB Regulatory Filings	2022-01-24	English
Employee Incentive Plan 20 pages 254.7KB Regulatory Filings	2022-01-24	English
Corporate Governance Statement 14 pages 339.5KB Regulatory Filings	2022-01-24	English
Securities Trading Policy 6 pages 270.6KB Regulatory Filings	2022-01-24	English
Distribution Schedule 1 page 66.5KB Regulatory Filings	2022-01-24	English
Top 20 Holders 2 pages 73.7KB Regulatory Filings	2022-01-24	English
Pre-Quotation Disclosure 4 pages 497.3KB Regulatory Filings	2022-01-24	English
Initial Director's Interest Notice - Phyllis Gardner 2 pages 250.6KB Regulatory Filings	2022-01-24	English
Initial Director's Interest Notice - Peter Molloy 2 pages 251.5KB Regulatory Filings	2022-01-24	English
Initial Director's Interest Notice - Stephen Goodall 2 pages 251.4KB Regulatory Filings	2022-01-24	English
Becoming a substantial holder - Firebrick Pharma 12 pages 542.0KB Regulatory Filings	2022-01-24	English
Becoming a substantial holder - Peter Molloy 3 pages 380.5KB Regulatory Filings	2022-01-24	English
Becoming a substantial holder - Stephen Goodall 3 pages 336.3KB Regulatory Filings	2022-01-24	English